Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 15/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 14/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 14/20 | 0.43 |
| ▸ | GABRP | O00591 | 12/20 | 0.43 |
| ▸ | GABRD | O14764 | 12/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 12/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 12/20 | 0.43 |
| ▸ | GABRE | P78334 | 12/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 12/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 12/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 12/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 12/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006735 | 1.00 | GABRB3 (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL3112325 | 0.90 | GABRP (0.48) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL3112330 | 0.90 | GABRP (0.48) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2002433 | 0.89 | GABRB3 (0.41) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2002434 | 0.89 | GABRB3 (0.41) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2004510 | 0.88 | GABRP (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2004509 | 0.88 | GABRP (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2003631 | 0.87 | GABRP (0.45) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2003630 | 0.87 | GABRP (0.45) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2002155 | 0.87 | GABRP (0.45) | GABRB3GABRA2GABRB2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1705989-B1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7435753-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
| US-20050148649-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | GABRB3 1185/4885GABRA2 1880/4885GABRB2 1662/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | GABRB3 1185/4885GABRA2 1880/4885GABRB2 1662/4885 |
| US-20050148649-A1 | Substituted arylpyrazoles | CYP3A4, CYP4B1, CYP1B1 | GABRB3 454/4885GABRA2 527/4885GABRB2 755/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | GABRB3 985/4885GABRA2 2134/4885GABRB2 1487/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | GABRB3 533/4885GABRA2 693/4885GABRB2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.